Main > PNEUMOLOGY > Cystic Fibrosis > Treatment > CFTR Modulation > Co.: USA. V. (Oral Corrector) > UpDate: 10.27.08

---

-- Vertex recently completed dosing in two Phase 1 trials of VX-809, an investigational oral CFTR corrector compound for the treatment of CF, in healthy volunteers. The first trial is a single and multiple dose study while the second is a single dose study examining the pharmacokinetics (PK) and safety of a solid dosage form. Based on these results, Vertex has initiated a single dose PK and safety trial of VX-809 in patients with CF. The Company plans to initiate a Phase 2a study in patients with CF in the first half of 2009.



UpDate: 10.27.08's products
This section has no products